An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
immunotherapy,
CEL-SCI,
infectious diseases,
leaps,
cancer,
autoimmune,
head and neck cancer,
squamous cell carcinoma,
rheumatoid arthritis,
covid19,
cervical dysplasia
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
Oncology,
Biologics,
Humanized monoclonal antibodies,
Immunoassay,
Immunogen,
Monoclonal antibody,
Antibody,
Contract research organization (CRO),
Customer relationship management (CRM),
Human monoclonal antibodies,
SARS-CoV-2,
Polyclonal antibody,
Contract manufacturing organization (CMO),
Enterprise resource planning (ERP)
An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
neurodegenerative,
multiple sclerosis,
inflammatory,
MS,
major depressive disorder (MDD),
myelin degradation,
bipilar disorder
An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
neurodegenerative,
fibrotic,
multiple sclerosis,
Huntingtons Disease,
cannabigerol,
SSc,
inflammatory,
systemic sclerosis,
MS,
Parkinsons Disease,
cannabinoids,
cannabidiol
An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
immunotherapy,
cancer,
autoimmune,
hepatocellular cancer,
GEN-1,
ovarian cancer,
interleukin-12,
IL-12,
ThermoDox,
primary liver cancer,
celsion
An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
immunotherapy,
CEL-SCI,
infectious diseases,
leaps,
cancer,
autoimmune,
head and neck cancer,
squamous cell carcinoma,
rheumatoid arthritis,
covid19,
cervical dysplasia
/SF_Healthcare_Conferences_2.jpg?width=355&name=SF_Healthcare_Conferences_2.jpg)
“Building a profile and becoming ‘known’ is a critical part of raising money…” — Erin Righetti, partnering360®
Healthcare conferences are in full swing this week in San Francisco, with attendees from companies large and small making the circuit at J.P. Morgan’s Annual Healthcare Conference, the EBD Group’s annual Biotech Showcase™, the StartUp Health Festival, and many others. From corporate presentations to strategic one-on-one meetings and even impromptu run-ins, networking opportunities abound and it is important for CEOs to be able to quickly, concisely, and effectively pitch their company to potential investors and/or partners.
Read More
Topics:
Crystal Research Associates,
biotech
Last week, Jeff Kraws sat down with Rhonda Schaffler at Reuters to discuss opportunities and trends in the biotech space. Mr. Kraws is a veteran Wall Street sell-side analyst with more than 20 years of experience and is also cofounder and CEO of Crystal Research Associates. If you enjoyed the short clip of this interview released earlier this week, the full segment (available below) goes into more detail on individual biotech stocks and the events every investor should be watching out for.
Read More
Topics:
AtheroNova,
Crystal Research Associates,
Unilife Corp.,
biotech,
MetaStat,
Reuters
Biotechnology--the use of living organisms or other biological systems in the manufacture of drugs or other products--has emerged as a critical sector for healthcare investors over the past several years. In 2012 alone, the biotech sector grew over 40% according to S&P Capital IQ. Biotech is expected to remain a hot market going forward, with considerable room for more growth. Last week, biotech firm Intrexon Corp. (XON-NYSE) made its IPO debut at $16/share and immediately soared 38%. Nearly double its IPO price, Intrexon opened at $29.99 this morning, August 13th.
Read More
Topics:
Crystal Research Associates,
Newsworthy Events,
biotech
Biotech company AtheroNova Inc. (AHRO-OTC) this morning announced that it raised over $2.9 million in gross proceeds from a sale of its Common Stock. This funding represents a major milestone for the company, as it is expected to support both Phase I and Phase II clinical trials for AtheroNova's anti-atherosclerotic plaque compounds in development. AtheroNova's most advanced product candidate, AHRO-001, works to significantly reduce the incidence and severity of plaque deposits, which are known to be the main underlying cause of cardiovascular disease, including heart attack, stroke, and peripheral artery disease (PAD).
Read More
Topics:
AtheroNova,
biotech
Last week in Boston, the NanoBusiness Commercialization Association (NanoBCA), a national nonprofit trade association for nanotechnology-enabled business, held a NanoBusiness conference where the association announced the "Top Nanotech Innovators of 2012," highlighting companies that create novel and potentially disruptive technologies in the nanotech sector. NanoBCA recognized 20 large corporations as well as 20 emerging enterprises. The Figure below highlights NanoBCA's view of the top nanotechnology innovators for 2012 and specifies the area(s) for which the company was recognized.
Read More
Topics:
nanotechnology,
biotech
New research available in our library at www.crystalra.com gives readers a complete description of the business of AtheroNova: its product development, milestones, competitive pressures, market opportunities, risks, and more. A 52-page report is available here, with future Quarterly Updates coming as AtheroNova advances this year.
Read More
Topics:
AtheroNova,
New Research,
biotech
We recently received an update from TapImmune Inc. (TPIV-OTC.BB) regarding the Company's newly acquired laboratory and office space in South Lake Union (Seattle's up-and-coming biotech hub). Through a strategic sublease with the Puget Sound Blood Center Research Institute, TapImmune's scientific research team now has access to shared equipment and state-of-the-art core laboratories for DNA sequencing, Mass Spectrometry (shown below), and Fluorescent Activated Cell Sorting (FACS)—a unique opportunity for any startup company.
Read More
Topics:
biotech,
TapImmune,
cancer vaccine,
immunotherapy,
Mark Reddish,
Puget Sound Blood Center
This has been a big week for healthcare and biotech.
Read More
Topics:
Crystal Research Associates,
NVIV,
GenSpera,
OneMedForum,
MedPro,
biotech,
Advaxis,
Peregrine,
Neuralstem,
Leslie Ziegler,
Gunnar Weikert,
PPHM,
General Cannabis,
SearchCore